International cooperation to address
and counter the world drug problem
A/RES/74/178
HIV prevention, treatment and care for injecting drug users, issued by the World
Health Organization, the United Nations Office on Drugs and Crime and the Joint
United Nations Programme on HIV/AIDS;
53. Urges Member States and other donors to continue to provide bilateral and
other funding for the global drug problem response, including in particular the
HIV/AIDS response, including to the Joint United Nations Programme on HIV/AIDS,
and to strive to ensure that such funding contributes to addressing the growing
HIV/AIDS epidemic among people who inject drugs, and HIV/AIDS in prison
settings, in the spirit of the pledge made in the 2030 Agenda for Sustainable
Development 9 to leave no one behind;
54. Acknowledges the continuing efforts made and the progress achieved in
countering the world drug problem, and stresses the need to str engthen and intensify
joint efforts at the national, regional and international levels to tackle the global
challenges related to the world drug problem in a more comprehensive manner, in
accordance with the principle of common and shared responsibility, i ncluding by
means of enhanced and better-coordinated technical and financial assistance;
55. Takes note of the 2018 report of the International Narcotics Control
Board 19 and the supplementary reports thereto, and in this regard reaffirms
Commission on Narcotic Drugs resolution 62/8 of 22 March 2019 on supporting the
International Narcotics Control Board in fulfilling its treaty-mandated functions in
cooperation with Member States and in collaboration with the Commission on
Narcotic Drugs and the World Health Organization; 2
56. Invites Member States to strengthen, as appropriate, the proper functioning
of national drug control systems and domestic assessment mechanisms and
programmes, in cooperation with the International Narcotics Control Board, the
United Nations Office on Drugs and Crime, the World Health Organization and other
relevant United Nations system agencies, to identify, analyse and remove
impediments to the availability and accessibility of control led substances for medical
and scientific purposes, within appropriate control mechanisms, as required by the
three international drug control conventions and taking into account the publication
entitled Ensuring Balance in National Policies on Controlled Substances: Guidance
for Availability and Accessibility of Controlled Medicines, and, for that purpose, to
consider the provision of technical and financial assistance, upon request, to
developing countries;
57. Urges all Member States to enact comprehensive measures aimed at
stemming the abuse, diversion and misuse of prescription drugs, in particular through
the establishment of awareness-raising initiatives targeting the general public and
health-care providers;
58. Recognizes that it is necessary for Member States, under the three
international drug control conventions and the fundamental principles of their
domestic legal systems and national legislation, to consider, where appropriate:
(a) Regularly reviewing and assessing their drug control policies, ensuring
that they are effective, comprehensive, balanced and aimed at promoting the health
and well-being of individuals, families, communities and society as a whole;
(b) Providing, as appropriate, comprehensive, integrated drug demand
reduction programmes, based on scientific evidence and covering a range of
measures, including primary prevention, early intervention, treatment, care,
rehabilitation, social reintegration and measures aimed at minimizing the negati ve
public health and social impact of drug abuse, aimed at promoting health and social
__________________
19
19-22335
International Narcotics Control Board, document E/INCB/2018/1.
13/23
Select target paragraph3
Connect to a paragraph
Connect to an entity
Disable highlights
Add to table of contents